Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.
about
Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effectsMyeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.Advances in the understanding of myeloma bone disease and tumour growth.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsIn vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells.The Analysis of the Relationship between Multiple Myeloma Cells and Their MicroenvironmentHigher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?Matricellular proteins as regulators of cancer metastasis to bone.Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity.Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.Bone marrow stromal cells show distinct gene expression patterns depending on symptomatically involved organs in multiple myeloma.Tumor-host cell interactions in the bone disease of myeloma.Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.Role of decorin in multiple myeloma (MM) bone marrow microenvironment.A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progressionDecorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration.Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma.The bone-marrow niche in MDS and MGUS: implications for AML and MM.New agents in the Treatment of Myeloma Bone Disease.Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?Multiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event
P2860
Q28730433-C94F0003-DD15-4C60-936F-420381B72C1AQ33558170-23574C7E-CEAC-4DCB-B949-639F8895FE98Q33574203-6C47C685-1ADC-44D6-AE85-CAC62E4F0171Q33829022-9A574A84-58D9-48D6-807E-726AA6ECF1DAQ34038854-E5A306C7-4C8E-4B46-8190-A7BE315095B7Q34501627-74C87DBC-A9F4-4D43-9AAC-6826B7B3FD43Q34652128-DC34E8E3-2E8A-4A87-B080-22C851C1CBD5Q34791709-8509BB09-B1D6-4EB8-B02B-EC9CC40834B8Q35778467-C8E6579A-3717-47DE-8103-19ACA4C0BB4DQ36289608-483286B3-BDD6-42C0-9432-62717055CE74Q36923653-13A6B058-9741-460B-A10B-E984387D956AQ36925154-111F7925-A1F9-4524-899A-8202F3BE5FA4Q37178131-428C63CF-17BB-44AC-BA22-EF6B83A33945Q37325029-5466B75D-42C4-41C8-A929-B0E757847E4BQ37771082-C4526F90-02A0-479B-83BA-D1000E083E02Q37953844-827CCBBE-DE7C-40ED-98F6-D810D11ED036Q38014834-095B32FF-ED17-4BC5-B19B-49617545A901Q38302987-C57B0025-8824-4CDA-B3EC-4014377C247DQ39030703-537ACE35-6BA6-42A4-B62D-F875077B1DCAQ39162516-D4E343DF-43DA-4950-9217-34EC963290C1Q39439676-BC2EE1C1-0384-4169-B26C-ECE2659E68CFQ42158465-EF520648-388C-4B61-AB35-D126943C5DF8Q43442169-2FC6FDC3-C141-492B-9DC3-30759D7D78ABQ50114615-A66BF8D3-3AFC-46E0-B900-95578B0BEE98Q50323850-C735A7D7-4664-4016-825D-9F645B1F74CDQ54448123-9276318E-5D9D-4673-9D4A-05E4E61582ACQ55471455-028B6D58-546E-4247-9676-F59419560B68Q58754109-00CDB20B-49E3-4116-914A-48ADF668A321
P2860
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Distinct transcriptional profi ...... multiple myeloma bone disease.
@en
Distinct transcriptional profi ...... multiple myeloma bone disease.
@nl
type
label
Distinct transcriptional profi ...... multiple myeloma bone disease.
@en
Distinct transcriptional profi ...... multiple myeloma bone disease.
@nl
prefLabel
Distinct transcriptional profi ...... multiple myeloma bone disease.
@en
Distinct transcriptional profi ...... multiple myeloma bone disease.
@nl
P2093
P50
P1476
Distinct transcriptional profi ...... multiple myeloma bone disease
@en
P2093
Andrea Facchini
Giorgio Lambertenghi-Deliliers
Katia Codeluppi
Manuela Abeltino
Monica Crugnola
Valentina Sgobba
Vittorio Rizzoli
P304
P356
10.1016/J.EXPHEM.2009.11.009
P50
P577
2009-12-04T00:00:00Z